PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI)

Q1 2017 13F Holders as of 31 Mar 2017

Type / Class
Equity / Common Stock
Shares outstanding
49,633,071
Total 13F shares
37,881,582
Share change
+4,991,772
Total reported value
$1,409,361,790
Put/Call ratio
79%
Price per share
$37.20
Number of holders
134
Value change
+$189,597,584
Number of buys
77
Number of sells
49

Institutional Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q1 2017

As of 31 Mar 2017, PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) was held by 134 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 37,881,582 shares. The largest 10 holders included ADAGE CAPITAL PARTNERS GP, L.L.C., FMR LLC, WELLINGTON MANAGEMENT GROUP LLP, VANGUARD GROUP INC, ORBIMED ADVISORS LLC, JANUS CAPITAL MANAGEMENT LLC, BlackRock Inc., Redmile Group, LLC, STATE STREET CORP, and PRICE T ROWE ASSOCIATES INC /MD/. This page lists 134 institutional shareholders reporting positions in this security for the Q1 2017 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.